Table of Content

1 Biologics and Biosimilars Market Overview
1.1 Product Overview and Scope of Biologics and Biosimilars
1.2 Biologics and Biosimilars Segment by Type
1.2.1 Global Biologics and Biosimilars Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Others
1.3 Biologics and Biosimilars Segment by Application
1.3.1 Global Biologics and Biosimilars Sales Comparison by Application: (2021-2027)
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Others
1.4 Global Biologics and Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Biologics and Biosimilars Revenue 2016-2027
1.4.2 Global Biologics and Biosimilars Sales 2016-2027
1.4.3 Biologics and Biosimilars Market Size by Region: 2016 Versus 2021 Versus 2027

2 Biologics and Biosimilars Market Competition by Manufacturers
2.1 Global Biologics and Biosimilars Sales Market Share by Manufacturers (2016-2021)
2.2 Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Biologics and Biosimilars Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Biologics and Biosimilars Manufacturing Sites, Area Served, Product Type
2.5 Biologics and Biosimilars Market Competitive Situation and Trends
2.5.1 Biologics and Biosimilars Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Biologics and Biosimilars Players Market Share by Revenue
2.5.3 Global Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Biologics and Biosimilars Retrospective Market Scenario by Region
3.1 Global Biologics and Biosimilars Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Biologics and Biosimilars Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Biologics and Biosimilars Market Facts & Figures by Country
3.3.1 North America Biologics and Biosimilars Sales by Country
3.3.2 North America Biologics and Biosimilars Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Biologics and Biosimilars Market Facts & Figures by Country
3.4.1 Europe Biologics and Biosimilars Sales by Country
3.4.2 Europe Biologics and Biosimilars Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Biologics and Biosimilars Market Facts & Figures by Region
3.5.1 Asia Pacific Biologics and Biosimilars Sales by Region
3.5.2 Asia Pacific Biologics and Biosimilars Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Biologics and Biosimilars Market Facts & Figures by Country
3.6.1 Latin America Biologics and Biosimilars Sales by Country
3.6.2 Latin America Biologics and Biosimilars Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Biologics and Biosimilars Market Facts & Figures by Country
3.7.1 Middle East and Africa Biologics and Biosimilars Sales by Country
3.7.2 Middle East and Africa Biologics and Biosimilars Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Biologics and Biosimilars Historic Market Analysis by Type
4.1 Global Biologics and Biosimilars Sales Market Share by Type (2016-2021)
4.2 Global Biologics and Biosimilars Revenue Market Share by Type (2016-2021)
4.3 Global Biologics and Biosimilars Price by Type (2016-2021)

5 Global Biologics and Biosimilars Historic Market Analysis by Application
5.1 Global Biologics and Biosimilars Sales Market Share by Application (2016-2021)
5.2 Global Biologics and Biosimilars Revenue Market Share by Application (2016-2021)
5.3 Global Biologics and Biosimilars Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Roche Biologics and Biosimilars Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Amgen Biologics and Biosimilars Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 AbbVie
6.3.1 AbbVie Corporation Information
6.3.2 AbbVie Description and Business Overview
6.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.3.4 AbbVie Biologics and Biosimilars Product Portfolio
6.3.5 AbbVie Recent Developments/Updates
6.4 Sanofi-Aventis
6.4.1 Sanofi-Aventis Corporation Information
6.4.2 Sanofi-Aventis Description and Business Overview
6.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
6.4.5 Sanofi-Aventis Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Corporation Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Pfizer Biologics and Biosimilars Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Novo Nordisk
6.6.1 Novo Nordisk Corporation Information
6.6.2 Novo Nordisk Description and Business Overview
6.6.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
6.7.5 Novo Nordisk Recent Developments/Updates
6.8 Eli Lilly
6.8.1 Eli Lilly Corporation Information
6.8.2 Eli Lilly Description and Business Overview
6.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
6.8.5 Eli Lilly Recent Developments/Updates
6.9 Novartis
6.9.1 Novartis Corporation Information
6.9.2 Novartis Description and Business Overview
6.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Novartis Biologics and Biosimilars Product Portfolio
6.9.5 Novartis Recent Developments/Updates
6.10 Merck
6.10.1 Merck Corporation Information
6.10.2 Merck Description and Business Overview
6.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Merck Biologics and Biosimilars Product Portfolio
6.10.5 Merck Recent Developments/Updates
6.11 3sbio
6.11.1 3sbio Corporation Information
6.11.2 3sbio Biologics and Biosimilars Description and Business Overview
6.11.3 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.11.4 3sbio Biologics and Biosimilars Product Portfolio
6.11.5 3sbio Recent Developments/Updates
6.12 Changchun High Tech
6.12.1 Changchun High Tech Corporation Information
6.12.2 Changchun High Tech Biologics and Biosimilars Description and Business Overview
6.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
6.12.5 Changchun High Tech Recent Developments/Updates
6.13 CP Guojian
6.13.1 CP Guojian Corporation Information
6.13.2 CP Guojian Biologics and Biosimilars Description and Business Overview
6.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
6.13.5 CP Guojian Recent Developments/Updates
6.14 Biotech
6.14.1 Biotech Corporation Information
6.14.2 Biotech Biologics and Biosimilars Description and Business Overview
6.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Biotech Biologics and Biosimilars Product Portfolio
6.14.5 Biotech Recent Developments/Updates
6.15 Gelgen
6.15.1 Gelgen Corporation Information
6.15.2 Gelgen Biologics and Biosimilars Description and Business Overview
6.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Gelgen Biologics and Biosimilars Product Portfolio
6.15.5 Gelgen Recent Developments/Updates
6.16 Innovent
6.16.1 Innovent Corporation Information
6.16.2 Innovent Biologics and Biosimilars Description and Business Overview
6.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Innovent Biologics and Biosimilars Product Portfolio
6.16.5 Innovent Recent Developments/Updates
6.17 Dong Bao
6.17.1 Dong Bao Corporation Information
6.17.2 Dong Bao Biologics and Biosimilars Description and Business Overview
6.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
6.17.5 Dong Bao Recent Developments/Updates
6.18 Ganlee
6.18.1 Ganlee Corporation Information
6.18.2 Ganlee Biologics and Biosimilars Description and Business Overview
6.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.18.4 Ganlee Biologics and Biosimilars Product Portfolio
6.18.5 Ganlee Recent Developments/Updates
6.19 United Laboratories
6.19.1 United Laboratories Corporation Information
6.19.2 United Laboratories Biologics and Biosimilars Description and Business Overview
6.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
6.19.5 United Laboratories Recent Developments/Updates

7 Biologics and Biosimilars Manufacturing Cost Analysis
7.1 Biologics and Biosimilars Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Biologics and Biosimilars
7.4 Biologics and Biosimilars Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Biologics and Biosimilars Distributors List
8.3 Biologics and Biosimilars Customers

9 Biologics and Biosimilars Market Dynamics
9.1 Biologics and Biosimilars Industry Trends
9.2 Biologics and Biosimilars Growth Drivers
9.3 Biologics and Biosimilars Market Challenges
9.4 Biologics and Biosimilars Market Restraints

10 Global Market Forecast
10.1 Biologics and Biosimilars Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Biologics and Biosimilars by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Biologics and Biosimilars by Type (2022-2027)
10.2 Biologics and Biosimilars Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Biologics and Biosimilars by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Biologics and Biosimilars by Application (2022-2027)
10.3 Biologics and Biosimilars Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Biologics and Biosimilars by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Biologics and Biosimilars by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Biologics and Biosimilars Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Biologics and Biosimilars Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Biologics and Biosimilars Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Biologics and Biosimilars Covered in This Study
Table 5. Global Biologics and Biosimilars Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Biologics and Biosimilars Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Biologics and Biosimilars Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Biologics and Biosimilars Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Biologics and Biosimilars Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Biologics and Biosimilars Manufacturing Sites and Area Served
Table 11. Manufacturers Biologics and Biosimilars Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biologics and Biosimilars as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Biologics and Biosimilars Sales by Region (2016-2021) & (K Units)
Table 16. Global Biologics and Biosimilars Sales Market Share by Region (2016-2021)
Table 17. Global Biologics and Biosimilars Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Biologics and Biosimilars Sales by Country (2016-2021) & (K Units)
Table 19. North America Biologics and Biosimilars Sales Market Share by Country (2016-2021)
Table 20. North America Biologics and Biosimilars Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Biologics and Biosimilars Revenue Market Share by Country (2016-2021)
Table 22. Europe Biologics and Biosimilars Sales by Country (2016-2021) & (K Units)
Table 23. Europe Biologics and Biosimilars Sales Market Share by Country (2016-2021)
Table 24. Europe Biologics and Biosimilars Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Biologics and Biosimilars Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Biologics and Biosimilars Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Biologics and Biosimilars Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Biologics and Biosimilars Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Biologics and Biosimilars Revenue Market Share by Region (2016-2021)
Table 30. Latin America Biologics and Biosimilars Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Biologics and Biosimilars Sales Market Share by Country (2016-2021)
Table 32. Latin America Biologics and Biosimilars Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Biologics and Biosimilars Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Biologics and Biosimilars Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Biologics and Biosimilars Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Biologics and Biosimilars Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Biologics and Biosimilars Revenue Market Share by Country (2016-2021)
Table 38. Global Biologics and Biosimilars Sales (K Units) by Type (2016-2021)
Table 39. Global Biologics and Biosimilars Sales Market Share by Type (2016-2021)
Table 40. Global Biologics and Biosimilars Revenue (Million US$) by Type (2016-2021)
Table 41. Global Biologics and Biosimilars Revenue Share by Type (2016-2021)
Table 42. Global Biologics and Biosimilars Price (USD/Unit) by Type (2016-2021)
Table 43. Global Biologics and Biosimilars Sales (K Units) by Application (2016-2021)
Table 44. Global Biologics and Biosimilars Sales Market Share by Application (2016-2021)
Table 45. Global Biologics and Biosimilars Revenue (Million US$) by Application (2016-2021)
Table 46. Global Biologics and Biosimilars Revenue Share by Application (2016-2021)
Table 47. Global Biologics and Biosimilars Price (USD/Unit) by Application (2016-2021)
Table 48. Roche Corporation Information
Table 49. Roche Description and Business Overview
Table 50. Roche Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. Roche Biologics and Biosimilars Product
Table 52. Roche Recent Developments/Updates
Table 53. Amgen Corporation Information
Table 54. Amgen Description and Business Overview
Table 55. Amgen Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. Amgen Biologics and Biosimilars Product
Table 57. Amgen Recent Developments/Updates
Table 58. AbbVie Corporation Information
Table 59. AbbVie Description and Business Overview
Table 60. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. AbbVie Biologics and Biosimilars Product
Table 62. AbbVie Recent Developments/Updates
Table 63. Sanofi-Aventis Corporation Information
Table 64. Sanofi-Aventis Description and Business Overview
Table 65. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. Sanofi-Aventis Biologics and Biosimilars Product
Table 67. Sanofi-Aventis Recent Developments/Updates
Table 68. Johnson & Johnson Corporation Information
Table 69. Johnson & Johnson Description and Business Overview
Table 70. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Johnson & Johnson Biologics and Biosimilars Product
Table 72. Johnson & Johnson Recent Developments/Updates
Table 73. Pfizer Corporation Information
Table 74. Pfizer Description and Business Overview
Table 75. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 76. Pfizer Biologics and Biosimilars Product
Table 77. Pfizer Recent Developments/Updates
Table 78. Novo Nordisk Corporation Information
Table 79. Novo Nordisk Description and Business Overview
Table 80. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 81. Novo Nordisk Biologics and Biosimilars Product
Table 82. Novo Nordisk Recent Developments/Updates
Table 83. Eli Lilly Corporation Information
Table 84. Eli Lilly Description and Business Overview
Table 85. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 86. Eli Lilly Biologics and Biosimilars Product
Table 87. Eli Lilly Recent Developments/Updates
Table 88. Novartis Corporation Information
Table 89. Novartis Description and Business Overview
Table 90. Novartis Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 91. Novartis Biologics and Biosimilars Product
Table 92. Novartis Recent Developments/Updates
Table 93. Merck Corporation Information
Table 94. Merck Description and Business Overview
Table 95. Merck Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 96. Merck Biologics and Biosimilars Product
Table 97. Merck Recent Developments/Updates
Table 98. 3sbio Corporation Information
Table 99. 3sbio Description and Business Overview
Table 100. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 101. 3sbio Biologics and Biosimilars Product
Table 102. 3sbio Recent Developments/Updates
Table 103. Changchun High Tech Corporation Information
Table 104. Changchun High Tech Description and Business Overview
Table 105. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 106. Changchun High Tech Biologics and Biosimilars Product
Table 107. Changchun High Tech Recent Developments/Updates
Table 108. CP Guojian Corporation Information
Table 109. CP Guojian Description and Business Overview
Table 110. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 111. CP Guojian Biologics and Biosimilars Product
Table 112. CP Guojian Recent Developments/Updates
Table 113. Biotech Corporation Information
Table 114. Biotech Description and Business Overview
Table 115. Biotech Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 116. Biotech Biologics and Biosimilars Product
Table 117. Biotech Recent Developments/Updates
Table 118. Gelgen Corporation Information
Table 119. Gelgen Description and Business Overview
Table 120. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 121. Gelgen Biologics and Biosimilars Product
Table 122. Gelgen Recent Developments/Updates
Table 123. Innovent Corporation Information
Table 124. Innovent Description and Business Overview
Table 125. Innovent Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 126. Innovent Biologics and Biosimilars Product
Table 127. Innovent Recent Developments/Updates
Table 128. Dong Bao Corporation Information
Table 129. Dong Bao Description and Business Overview
Table 130. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 131. Dong Bao Biologics and Biosimilars Product
Table 132. Dong Bao Recent Developments/Updates
Table 133. Ganlee Corporation Information
Table 134. Ganlee Description and Business Overview
Table 135. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 136. Ganlee Biologics and Biosimilars Product
Table 137. Ganlee Recent Developments/Updates
Table 138. United Laboratories Corporation Information
Table 139. United Laboratories Description and Business Overview
Table 140. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 141. United Laboratories Biologics and Biosimilars Product
Table 142. United Laboratories Recent Developments/Updates
Table 143. Production Base and Market Concentration Rate of Raw Material
Table 144. Key Suppliers of Raw Materials
Table 145. Biologics and Biosimilars Distributors List
Table 146. Biologics and Biosimilars Customers List
Table 147. Biologics and Biosimilars Market Trends
Table 148. Biologics and Biosimilars Growth Drivers
Table 149. Biologics and Biosimilars Market Challenges
Table 150. Biologics and Biosimilars Market Restraints
Table 151. Global Biologics and Biosimilars Sales Forecast by Type (2022-2027) & (K Units)
Table 152. Global Biologics and Biosimilars Sales Market Share Forecast by Type (2022-2027)
Table 153. Global Biologics and Biosimilars Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 154. Global Biologics and Biosimilars Revenue Market Share Forecast by Type (2022-2027)
Table 155. Global Biologics and Biosimilars Sales Forecast by Application (2022-2027) & (K Units)
Table 156. Global Biologics and Biosimilars Sales Market Share Forecast by Application (2022-2027)
Table 157. Global Biologics and Biosimilars Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 158. Global Biologics and Biosimilars Revenue Market Share Forecast by Application (2022-2027)
Table 159. Global Biologics and Biosimilars Sales Forecast by Region (2022-2027) & (K Units)
Table 160. Global Biologics and Biosimilars Sales Market Share Forecast by Region (2022-2027)
Table 161. Global Biologics and Biosimilars Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 162. Global Biologics and Biosimilars Revenue Market Share Forecast by Region (2022-2027)
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Biologics and Biosimilars
Figure 2. Global Biologics and Biosimilars Market Share by Type in 2020 & 2027
Figure 3. Monoclonal Antibodies Product Picture
Figure 4. Interferon Product Picture
Figure 5. Erythropoietin Product Picture
Figure 6. Insulin Product Picture
Figure 7. Vaccines Product Picture
Figure 8. Others Product Picture
Figure 9. Global Biologics and Biosimilars Market Share by Application in 2020 & 2027
Figure 10. Tumor
Figure 11. Diabetes
Figure 12. Cardiovascular
Figure 13. Hemophilia
Figure 14. Others
Figure 15. Global Biologics and Biosimilars Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Biologics and Biosimilars Market Size 2016-2027 (US$ Million)
Figure 17. Global Biologics and Biosimilars Sales 2016-2027 (K Units)
Figure 18. Global Biologics and Biosimilars Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 19. Biologics and Biosimilars Sales Share by Manufacturers in 2020
Figure 20. Global Biologics and Biosimilars Revenue Share by Manufacturers in 2020
Figure 21. The Global 5 and 10 Largest Biologics and Biosimilars Players: Market Share by Revenue in 2020
Figure 22. Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 23. Global Biologics and Biosimilars Sales Market Share by Region (2016-2021)
Figure 24. Global Biologics and Biosimilars Sales Market Share by Region in 2020
Figure 25. Global Biologics and Biosimilars Revenue Market Share by Region (2016-2021)
Figure 26. Global Biologics and Biosimilars Revenue Market Share by Region in 2020
Figure 27. U.S. Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Canada Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Germany Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. France Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. U.K. Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Italy Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Russia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. China Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Japan Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. South Korea Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. India Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Australia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Taiwan Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Indonesia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Thailand Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Malaysia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Philippines Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Vietnam Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Mexico Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Brazil Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Argentina Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Turkey Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 49. Saudi Arabia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 50. U.A.E Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 51. Sales Market Share of Biologics and Biosimilars by Type (2016-2021)
Figure 52. Sales Market Share of Biologics and Biosimilars by Application (2016-2021)
Figure 53. Sales Market Share of Biologics and Biosimilars by Application in 2020
Figure 54. Revenue Share of Biologics and Biosimilars by Application (2016-2021)
Figure 55. Revenue Share of Biologics and Biosimilars by Application in 2020
Figure 56. Manufacturing Cost Structure of Biologics and Biosimilars
Figure 57. Manufacturing Process Analysis of Biologics and Biosimilars
Figure 58. Biologics and Biosimilars Industrial Chain Analysis
Figure 59. Channels of Distribution
Figure 60. Distributors Profiles
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed